Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those wh...
Guardado en:
Autores principales: | Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Muriele Bertagna Varuzza, Cassio Murilo Trovo Hidalgo Filho, Vinicius Duval da Silva, Cristiano de Pádua Souza, Márcia Maria Chiquitelli Marques |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1f0be989ac644ef1b055811f264ef492 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram
por: Hao Cui, et al.
Publicado: (2021) -
Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Jin Hong, et al.
Publicado: (2021) -
A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
por: Du Y, et al.
Publicado: (2018) -
Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
por: Kamil D. Dalgatov, et al.
Publicado: (2021) -
Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)